Natera (NASDAQ:NTRA) Downgraded to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of Natera (NASDAQ:NTRA) from a buy rating to a hold rating in a research report sent to investors on Wednesday morning, Zacks.com reports.

According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “

A number of other research analysts have also issued reports on NTRA. BidaskClub lowered shares of Virtu Financial from a sell rating to a strong sell rating in a report on Wednesday, June 12th. Canaccord Genuity reiterated an average rating on shares of Kellogg in a report on Tuesday, June 25th. Finally, Piper Jaffray Companies set a $40.00 price objective on shares of Tapestry and gave the company a buy rating in a report on Monday, June 10th. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Natera has a consensus rating of Buy and a consensus target price of $30.14.



NTRA stock opened at $25.64 on Wednesday. The company has a market capitalization of $1.78 billion, a PE ratio of -11.93 and a beta of 1.51. The company has a debt-to-equity ratio of 20.88, a current ratio of 1.85 and a quick ratio of 1.73. Natera has a 12 month low of $11.08 and a 12 month high of $29.62. The business has a 50-day moving average of $24.89.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.05. The business had revenue of $66.82 million during the quarter, compared to analyst estimates of $66.40 million. Natera had a negative net margin of 49.33% and a negative return on equity of 699.31%. Sell-side analysts forecast that Natera will post -2.17 EPS for the current fiscal year.

In other Natera news, Chairman Matthew Rabinowitz sold 1,418 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $24.79, for a total transaction of $35,152.22. Following the completion of the sale, the chairman now owns 1,286,612 shares of the company’s stock, valued at approximately $31,895,111.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jonathan Sheena sold 1,033 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $24.79, for a total transaction of $25,608.07. Following the sale, the insider now directly owns 240,061 shares of the company’s stock, valued at approximately $5,951,112.19. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,771 shares of company stock valued at $140,742. 9.29% of the stock is owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the business. Legal & General Group Plc increased its position in Natera by 14.5% during the 4th quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock valued at $81,000 after purchasing an additional 736 shares during the period. JGP Global Gestao de Recursos Ltda. grew its position in shares of Natera by 10.5% during the 1st quarter. JGP Global Gestao de Recursos Ltda. now owns 13,518 shares of the medical research company’s stock worth $279,000 after buying an additional 1,280 shares during the period. Great West Life Assurance Co. Can grew its position in shares of Natera by 136.8% during the 4th quarter. Great West Life Assurance Co. Can now owns 5,920 shares of the medical research company’s stock worth $80,000 after buying an additional 3,420 shares during the period. Northern Trust Corp grew its position in shares of Natera by 1.1% during the 4th quarter. Northern Trust Corp now owns 430,391 shares of the medical research company’s stock worth $6,009,000 after buying an additional 4,706 shares during the period. Finally, NumerixS Investment Technologies Inc grew its position in shares of Natera by 86.5% during the 1st quarter. NumerixS Investment Technologies Inc now owns 13,616 shares of the medical research company’s stock worth $272,000 after buying an additional 6,316 shares during the period. 80.27% of the stock is owned by institutional investors and hedge funds.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Featured Article: Differences Between Momentum Investing and Long Term Investing

Get a free copy of the Zacks research report on Natera (NTRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.